One-session treatment of gonorrhoea in males with procaine penicillin plus probenecid*

R. J. C. COBBOLD
M.B.
Consultant Venereologist,
South-west Wales Group of Hospitals

G. D. MORRISON
M.B.
Senior Registrar,
United Bristol Group of Hospitals

R. J. SPITZER
M.B.
Consultant Venereologist,
Southend on Sea and Chelmsford Group of Hospitals

R. R. WILLCOX†
M.D.
Consultant Venereologist,
St Mary's Hospital, London, and King Edward VII Hospital, Windsor

Summary
Six hundred and thirteen male patients with acute uncomplicated gonorrhoea have been treated alternately with single injections of 1·2 mega-units of aqueous procaine penicillin alone or with the same dose and preparation of penicillin with an additional 1·0 g of probenecid given orally immediately prior to injection.

Whether the failure rates were assessed on the basis of an absence of further sexual exposure or by classifying all recurrences within 1 or 2 weeks regardless of history as treatment failures the results were significantly better when probenecid was also given.

The use of a single dose of probenecid is thus capable of maintaining the success of single injection procedures for the treatment of gonorrhoea based on procaine penicillin and thus represents a bulwark for the future should the powers of penicillin against the gonococcus in London deteriorate further.

Introduction
That failure rates to the treatment of gonorrhoea with penicillin have risen through the years owing to the development of resistance of the gonococcus to penicillin, necessitating higher routine dosages, is not in dispute (Willcox, 1968). In parts of the Far East a failure rate of 28·6% has been reported following single injections of 2·4 mega-units of aqueous procaine penicillin (Holmes, Johnson & Floyd, 1967) while in some local areas of this region a failure rate of 30% has been experienced follow-

* This work was done at St Mary's Hospital, London, W.2.
† Dr Willcox is a member of the World Health Organization Panel on Venereal Infections and Treponematoses.

Enhancement of procaine penicillin serum levels with probenecid
An alternative to increasing the dose of penicillin is to retain the existing dose and give the renal
tubular blocking agent probenecid which delays the excretion of penicillin.

There is a dearth of information regarding serum levels obtained with the larger doses (1-2 mega-units and above) of procaine penicillin. The estimations by White et al. (1956) of the serum levels obtained during the 6 hr following the administration of 1-2 mega-units of procaine penicillin with and without 1-0 g of probenecid given orally 1 hr before and again 5 hr after injection are shown in Table 1.

It is noted that the maximum, minimum and mean levels were heightened during this period by the use of probenecid and the differences between the maximum and minimum levels tended to be reduced after the 1st hour.

Clinical experience of probenecid in areas of high resistance

In areas of high resistance, inadequate schedules involving crystalline benzylpenicillin G have been made more adequate by the simultaneous use of probenecid (Jensen, Kvorning & Norredam, 1963). Complete success has been achieved in Greenland with single injections of 5 mega-units of crystalline penicillin G, dissolved in 8 ml of 0-5% lidocaine to obviate pain, combined with one oral dose of 1-0 g of probenecid given ½ hr before injection (Lomholt & Berg, 1966; Olsen & Lomholt, 1969). In the Far East the failure rate of 28-6% following single injections of 2-4 mega-units of aqueous procaine penicillin was reduced to only 2% if 1-0 g of probenecid was given 1 hr before injection followed by three doses each of 0-5 g at 6-hr intervals (Holmes et al., 1967) while in promiscuous women in Australia, Wren (1967) achieved complete success by combining 8-hourly injections of 2-0 mega-units of crystalline penicillin G combined with 2-0 g of probenecid daily for 2 days.

In this country only limited trials have in the past been undertaken with probenecid, but in combination with small doses of repository penicillins (Hilton, 1959). There is little or no information concerning the use of probenecid in one dose given simultaneously with an injection of aqueous procaine penicillin. It was thought worthwhile, therefore, to investigate this method under the conditions currently pertaining in London.

Case material and management

The study concerns 613 male patients with acute uncomplicated gonorrhoea treated at St Mary's Hospital. Alternate patients were given single injections of 1-2 mega-units of aqueous procaine penicillin or the same dose of procaine penicillin plus two 0-5 g tablets of probenecid, administered orally under supervision in the clinic.

Of the 306 patients receiving procaine penicillin alone 115 were born in the United Kingdom and 191 were immigrants, of whom 114 were Negroes. Of the 307 receiving probenecid in addition, 112 were born in the United Kingdom and 195 were immigrants of whom 111 were Negroes.

Although cultures were used in some cases diagnosis was based on Gram-stained urethral smears. Following treatment the patients were instructed to attend after 2–3 days. It was intended they should be subsequently seen at approximately 1, 2, 4, 8 and 12 weeks from treatment, but, as is common experience, by no means all patients attended at the times instructed.

Results obtained with procaine penicillin alone

The results obtained with 1-2 mega-units of procaine penicillin alone are shown in Table 2.
TABLE 2. Results obtained with 1-2 mega-units of procaine penicillin alone

<table>
<thead>
<tr>
<th>Length of follow-up</th>
<th>Followed</th>
<th>Satisfactory</th>
<th>Non-gonococcal urethritis</th>
<th>Reinfection</th>
<th>Failure</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>306</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>1-3 days</td>
<td>261</td>
<td>29</td>
<td>9</td>
<td>—</td>
<td>14</td>
</tr>
<tr>
<td>4-7 days</td>
<td>209</td>
<td>15</td>
<td>9</td>
<td>2</td>
<td>11</td>
</tr>
<tr>
<td>8-14 days</td>
<td>172</td>
<td>10</td>
<td>17</td>
<td>—</td>
<td>7</td>
</tr>
<tr>
<td>15-21 days</td>
<td>138</td>
<td>4</td>
<td>8</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>22-28 days</td>
<td>121</td>
<td>14</td>
<td>4</td>
<td>5</td>
<td>1</td>
</tr>
<tr>
<td>1-2 months</td>
<td>97</td>
<td>12</td>
<td>7</td>
<td>7</td>
<td>1</td>
</tr>
<tr>
<td>2-3 months</td>
<td>70</td>
<td>3</td>
<td>1</td>
<td>9</td>
<td>—</td>
</tr>
<tr>
<td>More than 3 months</td>
<td>57</td>
<td>27</td>
<td>16</td>
<td>14</td>
<td>—</td>
</tr>
<tr>
<td>Total</td>
<td>261</td>
<td>114</td>
<td>71</td>
<td>40</td>
<td>36</td>
</tr>
</tbody>
</table>

TABLE 3. Results obtained with 1-2 mega-units of procaine penicillin plus 1.0 g of probenecid

<table>
<thead>
<tr>
<th>Length of follow-up</th>
<th>Followed</th>
<th>Satisfactory</th>
<th>Non-gonococcal urethritis</th>
<th>Reinfection</th>
<th>Failure</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>307</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>1-3 days</td>
<td>264</td>
<td>22</td>
<td>7</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>4-7 days</td>
<td>232</td>
<td>30</td>
<td>10</td>
<td>1</td>
<td>7</td>
</tr>
<tr>
<td>8-14 days</td>
<td>184</td>
<td>27</td>
<td>20</td>
<td>1</td>
<td>7</td>
</tr>
<tr>
<td>15-21 days</td>
<td>129</td>
<td>7</td>
<td>7</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>22-28 days</td>
<td>111</td>
<td>11</td>
<td>4</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>1-2 months</td>
<td>92</td>
<td>13</td>
<td>3</td>
<td>7</td>
<td>0</td>
</tr>
<tr>
<td>2-3 months</td>
<td>69</td>
<td>6</td>
<td>1</td>
<td>6</td>
<td>—</td>
</tr>
<tr>
<td>More than 3 months</td>
<td>56</td>
<td>21</td>
<td>6</td>
<td>29</td>
<td>—</td>
</tr>
<tr>
<td>Total</td>
<td>264</td>
<td>137</td>
<td>58</td>
<td>51</td>
<td>18</td>
</tr>
</tbody>
</table>

TABLE 4. Comparison of results

<table>
<thead>
<tr>
<th>Schedule</th>
<th>Treated</th>
<th>Followed</th>
<th>Failure based on history</th>
<th>Recurrences within 1 week</th>
<th>Recurrences within 2 weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No.</td>
<td>%</td>
<td>No. %</td>
<td>No. %</td>
<td>No. %</td>
</tr>
<tr>
<td>Without probenecid</td>
<td>306</td>
<td>261</td>
<td>36 13.8</td>
<td>27 10.3</td>
<td>34 13.0</td>
</tr>
<tr>
<td>With probenecid</td>
<td>307</td>
<td>264</td>
<td>18 6.8</td>
<td>11 4.2</td>
<td>19 7.2</td>
</tr>
</tbody>
</table>

Thus of 306 patients treated 261 were followed and based on a history of no further sexual exposure there were adjudged to be thirty-six treatment failures of 13.8% of those followed.

No satisfactory criteria exist to distinguish relapse from reinfection apart from a history or absence of same of further sexual exposure. It has been shown by Curtis & Wilkinson (1958), however, on the basis of penicillin-sensitivity findings of the gonococci in question, that recurrences in the 1st week are likely to be failures and those after this time to be reinfections. Calculated in this way there were twenty-seven recurrences in the 1st week or 10.3% of those followed. Others have considered the dividing line of 2 weeks will provide a fairer assessment and the thirty-four recurrences noted in this time would give a failure rate of 13.0%.

Results obtained with procaine penicillin plus probenecid

The results obtained with 1-2 mega-units of procaine penicillin with 1.0 g of probenecid given orally immediately prior to injection are shown in Table 3.

Thus of 307 patients treated 264 were followed and based on no history of further sexual exposure there were eighteen failures (6.8% of those followed). If all eleven recurrences in the 1st week were taken as failures the failure rate was 4.2%, and if the
nineteen recurrences within 2 weeks were chosen the figure was 7.2%.

Comparison of results
The results obtained with the two schedules are compared in Table 4.
Thus by all three methods of assessment the results obtained were significantly better when additional probenecid was given.

Acknowledgment
Grateful thanks are expressed to Dr Geoffrey Rose, St Mary’s Hospital, London, W.2 for statistical advice.

References

One-session treatment of gonorrhoea in males with procaine penicillin plus probenecid

R. J. C. Cobbold, G. D. Morrison, R. J. Spitzer and R. R. Willcox

doi: 10.1136/pgmj.46.533.142

Updated information and services can be found at:
http://pmj.bmj.com/content/46/533/142

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/